ASTRA ZENECA
Alderley House, Alderley Park
Macclesfield, Cheshire SK10 4TF
UK
Tel: +44 1625 513560
Fax: +44 1625 582912
E-mail: susan.blewett@astrazeneca.com
Website: www.astrazeneca.com |
AstraZeneca is one of the world's
leading pharmaceutical companies and has over 40 years experience
in cardiovascular medicine. Underpinned by an extensive range
of respected landmark clinical studies, the AstraZeneca Cardiovascular
portfolio includes: Atacand®, Zestril®, Seloken ZOK®
/Toprol XL™.
Commitment to research is at the heart of AstraZeneca's success.
The AstraZeneca Cardiovascular research pipeline includes CRESTOR™,
an exciting and highly effective addition to the statin (HMGCoA
reductase inhibitor) class , Exanta, the first oral direct thrombin
inhibitor, and AZ 242, a novel treatment for type 2 diabetes
/ insulin resistance.
With corporate headquarters in London, UK, AstraZeneca has research
and manufacturing sites all over the world. The R&D headquarters
for Cardiovascular Medicine are based in Mölndal, Sweden. |
AXIS-SHIELD ASA
P.O. Box 206 Økern
N - 0510 Oslo
Norway
Tel.: +47 22700614
Fax: +47 22700770
E-mail: mette.smedbakken@no.axis-shield.com
Website: www.axis-shield.com
|
| Axis-Shield Lab Division area focuses
on selected areas - cardiovascular disease, autoimmune diseases,
infectious diseases and alcohol related diseases. In the cardiovascular
disease area, Axis-Shield is involved with two of the most exciting
new potential risk markers - homocysteine and Activated Factor
XIL. In addition an assay for the measurement of holo transcobalamin,
a potential marker for B12 deficiency, has newly been launched. |
BIOSCIENCE EDIPRINT INC.
16, rue A. Gavard
1227 Geneva
Switzerland
Tel: + 41 22 300 33 83
Fax: + 41 22 300 24 89
E-mail: Bioscience.smey@gkb.com |
| Bioscience Ediprint Inc. is an international
publisher specialized in medical publications aimed towards
hospitals, universities, clinics and research centers. Special
attention is given to publications for official institutions
(governmental and non-governmental) and to pharmaceutical companies.
Journal titles include Drugs under Experimental and Clinical
Research, which is focused on new drug discoveries and in
vitro and in vivo trials; International Journal of Immunotherapy,
which is devoted to the latest compounds in anticancer and
anti-inflammatory immunotherapy; International Journal of
Tissue Reactions, which covers the basic aspects of anticancer,
anti-inflammatory and gastrointestinal diseases; and, International
Journal of Clinical Pharmacology Research, devoted to the
latest results related to new drugs and clinical trials.
Special issues on selected topics are also published either
as a complete volume or specialized number of the journal.
|
BIT BUREAU FOR INTERNATIONAL RESEARCH AND TECHNOLOGY CO-OPERATION
Donau-City-Str.1
A-1220 Vienna
Austria
Tel: +43 1 581 1616 131
Fax: + 43 1 581 1616 16
E-mail: bit@bit.ac.at
Website: www.bit.ac.at |
Creating awareness and informing on EU and
international RTD activities, e.g. in 6th Framework Programme.
Identifying potential Austrian parties interested in transnational
RTD co-operation.
Assisting in the search for partners in Austria and other eligible
countries
Assisting in preparing proposals, supporting in the dissemination
of research results and the transfer of new technologies. |
B. BRAUN MEDIZINTECHNOLOGIE GmbH
Schwarzenberger Weg 73-79
D-34212 Melsungen
Germany
Tel: +49 5661 713 521
Fax: +49 5661 713 510
E-mail: dietmar.clargel@bbraun.com
Web site: www.bbraun.com |
| Products for extracorporeal blood treatment
(dialysis and H.E.L.P. -apheresis). |
ELSEVIER SCIENCE
Molenwerf 1
1014 AG Amsterdam
The Netherlands
Tel. +31 20 485 3799
Fax +31 20 485 3809
E-mail: e.patman@elsevier.nl
Website: www.elsevier.com |
Elsevier Science, the publishing
partner of some of the world's leading organisations, plays
a key role in disseminating scientific information in medical
journals, books and electronic products.
On display are esteemed journals like Atherosclerosis, the official
Journal of the European Atherosclerosis Society and affiliated
with the International Atherosclerosis Society, European Journal
of Heart Failure and the recently launched European Journal
of Cardiovascular Nursing, Thrombosis Research (including Vessels)
and many, many more.
Electronic initiatives include: ScienceDirect, ContentsDirect,
and CardioSource.
Free sample copies and recently published books are on display
at the booth. For a complete overview of the program please
visit: www.elsevier.com
|
LIPID SCIENCES, INC.
7068 Koll Center Parkway, Suite 401
Pleasanton, CA 94566
USA
Tel: +1 925-249-4050
Fax: +1 925-249-4040
E-mail: drichardson@lipidsciences.com
Website: www.lipidsciences.com |
| Lipid Sciences, Inc. is developing
a technology to reverse atherosclerosis. They have developed
a vascular lipid removal system, which sytemically removes lipids
from plasma lipoproteins. The technology only removes the lipid
component of the particle without adversly affecting lipoproteins,
leaving the particle intact and functional. Preclinical studies
have domonstrated reverse cholesterol transport in animals.
A human safety study is currently being conducted and European
trials are planned for 2003. |
MSD
MERCK & CO., INC
WS2C-36A
P.O. Box 100. One Merck Drive
Whitehouse Station, NJ 08889
USA
Tel: +1 908 423 2774
Fax: +1 908 735 1685 |
| ZOCOR® (simvastatin, MSD), an
HMG-CoA reductase inhibitor, is indicated to reduce elevated
total and DL cholesterol and triglycerides, and to increase
HDL cholesterol in patients with hyperlipidemia. In patients
with coronary heart disease, ZOCOR is indicated to reduce the
risk of death, coronary death and non-fatal MI; stroke and TIA;
revascularization procedures, and to slow the progression of
coronary atherosclerosis. As shown in the 4S study, ZOCOR 20-40mg
reduced the risk of total death by 30 percent and the risk of
coronary death by 42 percent. ZOCOR has been in clinical use
for 15 years and has been prescribed for more than 40 million
patients worldwide.
Merck & Co. is an international pharmaceutical
and healthcare company researching and providing medicines
for patients in a diverse range of disease categories.
|
MERCODIA AB
Sylveniusgatan 8A
75450 Uppsala
Sweden
Tel: +46 18 570 070
Fax: +46 18 570 080
E-mail: Christina.axelsson@mercodiaa.se |
Mercodia is featuring an arteriosclerosis
marker the "oxLDL ELISA Assay"
based on monoclonal antibodies to oxidized low density protein.
Mercodia develops, manufactures and distributes advanced ELISA
assays, based on monoclonal antibody technology, for use in
a variety of diagnostic and research applications within the
field of cardiovascular disease and diabetes. |
MONDUZZI EDITORE S.P.A.
International Proceedings Division
Via Ferrarese 119/2
40128 Bologna
Italy
Tel: +39 051 4151111
Fax: +39 051 370529
E-mail: gamberini@monduzzi.com |
MSD - SP Limited
One Merck Drive, WS2C36A,
Whitehouse Station, NJ, 08889
USA
Tel: +1 908 423 2774
Fax: +1 908 735 1685
Email: smithj@merck.com
|
Ezetimibe (eh-ZET-i-mibe) is an investigational
new drug and, will be when approved for use, the first drug
in a new class of cholesterol lowering medications. In clinical
trials, ezetimibe plus a statin provided LDL-c lowering of an
additional 25% when added to ongoing statin therapy, HDL-c and
reduced triglycerides without compromising patient safety.
The distinct mechanism of action of ezetimibe complements the
effects of statins. Ezetimibe works by a novel mechanism in
the cells that line the wall of the small intestine to selectively
inhibit the intestinal absorption of cholesterol. Unlike bile
acid sequestrants, ezetimibe does not physically bind bile acids.
Ezetimibe is not a resin, fat-blocker, stanol or sterol. In
clinical trials, ezetimibe had a side effect profile comparable
to placebo, did not induce cytochrome P-450 (CYP450) drug metabolizing
enzymes and has no clinically significant drug interactions.
Ezetimibe is administered as one tablet taken once daily at
any time, with or without meals. |
PFIZER Inc.
235 East 42nd Street
New York, NY, 10017 - 5755
USA
Tel: +1 212 573 2323
Fax: +1 212 309 4462
Website: www.pfizer.com |
| Pfizer, a world leader in cardiovascular
research, is dedicated to help improve the management of cardiovascular
disease. Their commitment to innovative R&D has led to the
development of products that have the potential to dramatically
improve the care of patients with cardiovascular disease. These
products include LIPITOR® (atorvastatin calcium tablets),
NORVASC® (amlodipine besylate), and ACCUPRIL® (quinapril
hydrochloride tablets). |
RHEOLOGICS
15 East Uwchlan Avenue, Suite 414
Exton, PA 19341
USA
Tel: +1 610 524 5427
Fax: +1 610 524 9440
E-mail : djohnson@rheologics.com
Website : www.rheologics.com |
SANKYO PHARMA GmbH
Zielstattstr. 9
D - 81379 Munich
Germany
Tel.: +49 89 7808-0
Fax: +49 89 7808-267
Website: www.sankyo-pharma.com |
| Sankyo is Japan's second-largest pharmaceutical
company. Sankyo is represented in the major European countries
through subsidiaries. Among Sankyo's products are cefpodoxime,
a third-generation oral cephalosporin and pravastatin, a HMG-CoA
reductase inhibitor or statin. Pravastatin is still the statin
with the broadest indications, both in primary and secondary
prevention and has the largest body of evidence from prospective
long-term clinical trials. With olmesartan medoxomil, a new
angiotensin II antagonist, Sankyo will further expand its competence
in the field of cardiovascular disease. |
WISEPRESS BOOKSHOP
The Old Lamp Works
25 High Path, Merton Abby
London SW19 2JL
UK
Tel: +44 208 715 1812
Fax: +44 208 715 1722
E-mail: penny@wiswpress.co.uk
Website: www.wisepress.co.uk |
| Publications |
